Insmed (INSM) Liabilities and Shareholders Equity (2011 - 2026)

Insmed's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 15.15% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 19.37% YoY), while the FY2025 annual figure was $2.3 billion, up 11.82% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $2.1 billion, down from $2.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $2.5 billion in Q2 2025, with the low at $994.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2022), against an average of $1.7 billion.
• Peak annual rise in Liabilities and Shareholders Equity reached 66.57% in 2022, while the deepest fall reached 24.16% in 2022.
• Insmed's Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then fell by 19.72% to $1.3 billion in 2023, then jumped by 52.29% to $2.0 billion in 2024, then advanced by 11.82% to $2.3 billion in 2025, then dropped by 8.33% to $2.1 billion in 2026.
• Business Quant data shows INSM's Liabilities and Shareholders Equity at $2.1 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.4 billion in Q3 2025.